October 16, 2020  

Celloram successfully closes its 8M Seed Series Round

Celloram successfully closed its $8M Seed Series Round, securing funds to advance its mission of developing safer and more effective treatments for cancer, immune and metabolic disorders. Seed Series investors include MedPacto Inc., Theragen Etex, and Winvest, among others.

Celloram’s research pipelines focus on both innovative cell therapies and novel small molecule therapeutics, with primary indications including difficult-to-treat triple negative breast cancer (TNBC) and graft-versus-host disease (GVHD). The Seed Series funds will allow Celloram to expand its research team and facilities and provide continued support of the development of novel therapies for these critical disease indications.

January 7, 2020  

Celloram is awarded $0.2M DOD Grant to improve Post-Trauma-Induced Osteoarthritis

Celloram was awarded a $0.2M grant from the U.S. Department of Defense to improve post-trauma induced osteoarthritis. Osteoarthritis is a leading cause of mobility-related disability and is usually induced by the gradual wearing-down of joint cartilage over time. Post-trauma induced osteoarthritis, or PTOA, is a subtype of osteoarthritis that develops after joint injury and therefore disproportionality effects a young population.

Many PTOA cases recover within 6 months, but some cases can develop into chronic disease. The activation of inflammatory mechanisms is thought to play an important role in the progression of acute to chronic disease, so early interventions are of interest. Celloram hopes that by applying its innovative cell therapy technologies that work with the power of the immune system, we can develop early-intervention therapies to treat this debilitating chronic condition.

January 3, 2020  

Dr. Liraz Levi joins as VP and Director of Scientific Operations, Small Molecule Program

Dr. Liraz Levi joins Celloram as VP and Director of Scientific Operations of our Small

Molecule Program. Dr. Levi completed her Ph.D. at The Hebrew University of

Jerusalem and previously served as a principal investigator in the Case Comprehensive

Cancer Center at Case Western Reserve University.

Dr. Levi’s research began with an interest in dietary nutrients and how they affect

molecular processes in the body. Her research has since expanded into how fatty acids

and other small molecules can enhance or disrupt the processes that regulate cancer

cells and metabolic diseases.

Dr. Levi is a welcome and valued addition to Celloram and our Small Molecule Program.

January 3, 2019  

Dr. Seunghwan Lim joins Celloram as VP and Director of Scientific Operations of our Cell Therapy Program

Dr. Seunghwan Lim joins Celloram as VP and Director of Scientific Operations of our Cell Therapy Program. Dr. Lim completed his Ph.D. in cancer biology and therapeutics development at SUNY Upstate Medical University and his postdoctoral training at the National Cancer Institute, NIH and Case Western Reserve University.

His research interests largely focus on cellular signaling events, specifically the TGF-β signaling pathway. TGF-β is a multifunctional cytokine that plays an important role in regulating malignant cancer behaviors.

“With over 20 years of research experiences, I feel like I have to use this knowledge to develop something more special that can save some lives” says Dr. Lim.

We are thrilled to welcome Dr. Lim to Team Celloram.